At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 581 enrolled
Drug / intervention
SAGE-217 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating SAGE-217 and Placebo for Major Depressive Disorder. Completed, enrolled 581 participants across 53 sites.
Detailed Summary
This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionSep 2019
Study CompletionMar 2020
TodayJul 2026
First PostedSep 14, 2018
Enrollment StartNov 19, 2018
Primary CompletionSep 24, 2019
Study CompletionMar 17, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.8 years ago
Interventions
SAGE-217drug
SAGE-217 hard gelatin capsules.
Placebodrug
SAGE-217 matched placebo hard gelatin capsules.